🖐️ Vasodilator Drug Comparison Simulator (CCBs vs PDE5 Inhibitors vs Topical Nitrates)

Baseline Digital Vasospasm in Raynaud's Phenomenon

Cold or stress triggers exaggerated digital artery constriction, cutting blood flow.

• >75%: Digital artery narrowing (during an episode)
• 15–20 min: Episode duration (typical attack)
• 3–5%: Prevalence (of general population)
• Upregulated: Alpha-2 receptor role (cold-induced vasoconstriction)

Vascular smooth muscle overactivity

Cold triggers alpha-2 receptor–driven calcium influx and spasm.

Primary vs secondary Raynaud's

Secondary forms, e.g. scleroderma, risk digital ulceration.

Why vasodilators are first-line

Restoring nitric oxide / calcium balance reopens the vessel.

Choosing a Vasodilator Mechanism

Three drug classes act on distinct steps of the vasodilation pathway.

• ~90%: CCB first-line use (of prescribed cases)
• 2nd-line: PDE5i typical use (refractory / ulcer cases)
• Local: Topical nitrate site (applied to digit)
• 3: Classes compared (CCB, PDE5i, nitrate)

Calcium channel blockers (dihydropyridines)

Systemic L-type calcium channel blockade, first-line therapy.

PDE5 inhibitors

Preserve cGMP, potentiate nitric-oxide–driven relaxation.

Topical nitrates

Deliver nitric oxide directly, minimizing systemic exposure.

Mechanism-Specific Smooth Muscle Relaxation

Each class relaxes vascular smooth muscle through a different molecular route.

• +55%: CCB lumen gain (at high dose)
• +50%: PDE5i lumen gain (cGMP-mediated)
• +45%: Nitrate lumen gain (localized NO release)
• Ca²⁺↓: Shared endpoint (in smooth muscle cell)

Calcium channel blockade

Blocked channels cut calcium influx, muscle relaxes.

cGMP amplification pathway

PDE5 blocked, cGMP accumulates, sustains relaxation signal.

Direct nitric oxide donation

Nitrate releases NO at the skin, local vessels dilate.

Onset, Side-Effect Burden, and Indications Compared

Trade-offs in speed, systemic effects, and ulcer benefit guide selection.

• Nitrate: Fastest onset (localized action)
• CCB: Highest side burden (flushing, edema, hypotension)
• PDE5i: Best ulcer healing (enhanced microcirculation)
• Nitrate: Lowest systemic burden (minimal absorption)

Onset speed comparison

Nitrate acts fastest; PDE5i is slowest to take effect.

Systemic side-effect burden

CCB carries the most systemic burden; nitrate the least.

Indication-specific benefit

PDE5i favored for scleroderma-associated digital ulcers.

Vasodilator class comparison

Matching Therapy to Severity, Ulcers, and Tolerance

Real-world selection weighs severity, ulcer presence, and side-effect tolerance.

• CCB: First-line choice (mild–moderate disease)
• PDE5i: Ulcer-present choice (add-on or switch)
• Nitrate: Poor CCB tolerance (localized alternative)
• Combination: Refractory cases (CCB + PDE5i ± nitrate)

Stepwise treatment approach

Start CCB, add or switch agents as severity dictates.

Combination therapy for refractory disease

Combined mechanisms improve outcomes when monotherapy fails.

Individualized decision-making

Balance efficacy, tolerability, and ulcer risk per patient.